EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

被引：0
|
作者：
Sandborn, William J.
Ferrante, Marc
Bhandari, Raj
D'Haens, Geert
Berliba, Elina
Feagan, Brian G.
Klekotka, Paul
Laskowski, Janelle
Durante, Michael
Tuttle, Jay L.
Naegeli, April
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P033
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [41] Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide
    Nikki McCaffrey
    Tegan Asser
    Belinda Fazekas
    Wendy Muircroft
    Meera Agar
    Katherine Clark
    Simon Eckermann
    Jessica Lee
    Rohit Joshi
    Peter Allcroft
    Caitlin Sheehan
    David C. Currow
    BMC Cancer, 20
  • [42] VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis
    Schreiber, Stefan
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Sands, Bruce E.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S612 - S613
  • [43] An international phase III, randomised, controlled trial evaluating health-related quality of life in glioblastoma patients
    Taphoorn, MJB
    Stupp, R
    Osoba, D
    Curschmann, J
    Kortmann, R
    van den Bent, M
    Mason, W
    Coens, C
    Eisenhauer, E
    Bottomley, A
    NEURO-ONCOLOGY, 2004, 6 (04) : 358 - 358
  • [44] The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis
    Hjortswang, H
    Järnerot, G
    Curman, B
    Sandberg-Gertzén, H
    Tysk, C
    Blomberg, B
    Almer, S
    Ström, M
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (09) : 1011 - 1020
  • [45] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
    Deodhar, Atul
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth C.
    LANCET, 2018, 391 (10136): : 2213 - 2224
  • [46] Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study
    Sandborn, W. J.
    Cyrille, M.
    Hansen, M. B.
    Feagan, B. G.
    Loftus, E. V., Jr.
    Rogler, G.
    Vermeire, S.
    Cruz, M. L.
    Yang, J.
    Sullivan, B. A.
    Reinisch, W.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S21 - S22
  • [47] RETRACTED: EFFICACY, SAFETY, AND TOLERABILITY OF OMILANCOR IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS (Retracted Article)
    Leber, Andrew
    Hontecillas, Raquel
    Tubau-Juni, Nuria
    Lichtiger, Simon
    Bassaganya-Riera, Josep
    GASTROENTEROLOGY, 2022, 162 (03) : S112 - S112
  • [48] Impact of MMX® Mesalamine on Improvement and Maintenance of Health-Related Quality of Life in Patients with Ulcerative Colitis
    Hodgkins, Paul
    Yen, Linnette
    Yarlas, Aaron
    Karlstadt, Robyn
    Solomon, Dory
    Kane, Sunanda
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (02) : 386 - 396
  • [49] Improvement in Health-Related Quality of Life Following Treatment With MMX® Mesalamine in Patients With Ulcerative Colitis
    Kane, Sunanda V.
    Yen, Linnette
    Yarlas, Aaron
    Karlstadt, Robyn G.
    Solomon, Dory M.
    Hodgkins, Paul
    GASTROENTEROLOGY, 2010, 138 (05) : S319 - S319
  • [50] The Impact of Endoscopic Inflammation and Mucosal Healing on Health-related Quality of Life in Ulcerative Colitis Patients
    Theede, Klaus
    Kiszka-Kanowitz, Marianne
    Nordgaard-Lassen, Inge
    Nielsen, Anette Mertz
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (08): : 625 - 632
12345